Open AccessPhase I trial of combination of FOLFIRI and pasireotide, a somatostatin analogue, in advanced gastrointestinal malignancies
Author(s) -
Amit Mahipal,
David Shibata,
Erin M. Siegel,
Gregory M. Springett,
Khaldoun Almhanna,
William J. Fulp,
Irene Williams-Elson,
Richard Kim
Publication year - 2015
Publication title -
investigational new drugs
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.254
H-Index - 87
eISSN - 1573-0646
pISSN - 0167-6997
DOI - 10.1007/s10637-015-0277-8
Subject(s) - pasireotide , medicine , folfiri , tolerability , gastroenterology , irinotecan , adverse effect , regimen , oncology , phases of clinical research , combination therapy , colorectal cancer , pharmacology , chemotherapy , cancer , acromegaly , growth hormone , hormone
Pasireotide (SOM230) is a somatostatin analog with high binding affinity for somatostatin receptors including sst1, 2, 3 and 5 and inhibit insulin like growth factor-1. Blocking of IGF-1 receptor (IGF-1R) in combination with cytotoxic chemotherapy has demonstrated additive or synergistic activity in pre-clinical models. This study aimed to evaluate the maximum tolerated dose (MTD) of pasireotide in combination with standard FOLFIRI (5-fluorouracil, leucovorin and irinotecan) regimen in patients with gastrointestinal malignancies.